Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Articles in E-pub version are posted online ahead of regular printed publication.

Original Article

Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017-2023

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Received November 3, 2024 Accepted November 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0987 [Accepted]

View: 142 Download: 16

Correspondence

HCV Self-Testing: Bridging Screening Gaps and Ensuring Cost-Effectiveness for Both High-Risk and Universal Populations

Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn

Received November 23, 2024 Accepted November 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1057 [Accepted]

View: 65 Download: 8

Review

Microbiome-Centered Therapies for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Received September 13, 2024 Accepted November 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811 [Accepted]

View: 334 Download: 41

Liquid Biopsy in Hepatocellular Carcinoma: Challenges, Advances, and Clinical Implications

Jaeho Park, Yi-Te Lee, Vatche G. Agopian, Jessica S Liu, Ekaterina K. Koltsova, Sungyong You, Yazhen Zhu, Hsian-Rong Tseng, Ju Dong Yang

Received July 10, 2024 Accepted November 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0541 [Accepted]

View: 137 Download: 16

Letter to the Editor

Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus

Xinpu Miao, Haidong Wu, Jinrong Xu, Wei Cheng

Received November 18, 2024 Accepted November 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.1035 [Accepted]

View: 84 Download: 1

Grading Severity of Microvascular Invasion in Hepatocellular Carcinoma: More Details, More Significance

Xiu-Ping Zhang, Fei-Fan Wu, Tian-Chen Zhang, Zhen-Qi Li, Ming-Gen Hu, Rong Liu

Received November 3, 2024 Accepted November 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0986 [Accepted]

View: 112 Download: 14

Review Article

Mechanisms of HCC and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Received September 25, 2024 Accepted November 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837 [Accepted]

View: 285 Download: 39

Original Article

TIPS insertion leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis

Anja Tiede, Lena Stockhoff, Zhaoli Liu, Hannah Rieland, Jim B. Mauz, Valerie Ohlendorf, Birgit Bremer, Jennifer Witt, Anke Kraft, Markus Cornberg, Jan B. Hinrichs, Bernhard C. Meyer, Heiner Wedemeyer, Cheng-Jian Xu, Christine S. Falk, Benjamin Maasoumy

Received July 22, 2024 Accepted November 18, 2024

DOI: https://doi.org/10.3350/cmh.2024.0587 [Accepted]

View: 238 Download: 38

Bariatric Surgery Reduces Long-Term Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Cirrhosis

Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen

Received July 15, 2024 Accepted November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0564 [Accepted]

View: 532 Download: 29

Review

Prospect of emerging treatments for HBV functional cure

Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen

Received September 29, 2024 Accepted November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0855 [Accepted]

View: 403 Download: 83

Correspondence

Reply to “Insights on Risk Score Development: Considerations for Early-Stage Hepatocellular Carcinoma Models”

Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su

Received November 6, 2024 Accepted November 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0999 [Accepted]

View: 117 Download: 2

Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”

Yu-Hang Ye, Shao-Lai Zhou

Received November 6, 2024 Accepted November 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0998 [Accepted]

View: 159 Download: 3

Reply to Correspondence

Letter to the Editor Clinical and Molecular Hepatology Correspondence on the Editorial regarding “The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients”

Mirko Zoncapè, Emmanuel A. Tsochatzis

Received November 5, 2024 Accepted November 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0994 [Accepted]

View: 132 Download: 2

Editorial

Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea

Eun Sun Jang

Received November 5, 2024 Accepted November 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0992 [Accepted]

View: 105 Download: 4

Correspondence

Correspondence to editorials on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”

Woo Hyun Paik, Do Hyun Park

Received November 4, 2024 Accepted November 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0989 [Accepted]

View: 149 Download: 11

Review

Hepatitis E as a trigger for Acute-on-Chronic Liver Failure

Maria Buti, Juan Carlos Ruiz-Cobo, Rafael Esteban, Mar Riveiro-Barciela

Received September 5, 2024 Accepted November 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0758 [Accepted]

View: 322 Download: 42

Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment

Atsumasa Komori, Yuki Kugiyama

Received September 20, 2024 Accepted November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0821 [Accepted]

View: 316 Download: 77

Stem cell exosomes: new hope and future potential for relieving liver fibrosis

Lihua Li, Yongjie Liu, Kunpeng Wang, Jinggang Mo, Zhiyong Weng, Hao Jiang, Chong Jin

Received September 29, 2024 Accepted November 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0854 [Accepted]

View: 525 Download: 75

Letter to the Editor

Insights on Risk Score Development: Considerations for Early-Stage Hepatocellular Carcinoma Models

Zhanna Zhang, Gongqiang Wu

Received October 28, 2024 Accepted November 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0958 [Accepted]

View: 186 Download: 14

Editorial

Stabilizing Hepatic Fatty Acid Oxidation: USP29 Secures Acyl-CoA Synthesis through ACSL5

Myeung Gi Choi, Na Young Lee, Ja Hyun Koo

Received October 31, 2024 Accepted November 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0971 [Accepted]

View: 169 Download: 21

Reply to Correspondence

Reply to correspondence on “Understanding the impact on digestive disease in the post-COVID-19 condition”

Yang-Hyun Baek

Received October 30, 2024 Accepted November 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0966 [Accepted]

View: 143 Download: 3

Correspondence

Reply to “Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma”

Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su

Received October 25, 2024 Accepted November 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0946 [Accepted]

View: 160 Download: 3

Editorial

A novel clinical trial for primary sclerosing cholangitis from Asia: all regional endeavors should improve global management of PSC

Atsumasa Komori

Received October 25, 2024 Accepted November 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0945 [Accepted]

View: 195 Download: 19

Correspondence

Correspondence on Letter Regarding “Contemporary Awareness of Viral Hepatitis between 2012 and 2022 among Korean Adults”

Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong

Received October 25, 2024 Accepted November 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0944 [Accepted]

View: 151 Download: 2

Correspondence on Letter regarding “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”

Moon Haeng Hur, Yoon Jun Kim

Received October 25, 2024 Accepted November 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0943 [Accepted]

View: 210 Download: 12

Editorial

Challenges and Innovations in PSC Clinical Trials: Evaluating HK-660S and the Path Forward

Nilanga Nishad

Received October 24, 2024 Accepted October 31, 2024

DOI: https://doi.org/10.3350/cmh.2024.0942 [Accepted]

View: 170 Download: 11

Correspondence

Response to the letter

Hee Yeon Kim, Miyoung Choi, Dae Won Jun

Received October 23, 2024 Accepted October 31, 2024

DOI: https://doi.org/10.3350/cmh.2024.0937 [Accepted]

View: 152 Download: 8

Review

ALCOHOL-ASSOCIATED LIVER DISEASE: NATURAL HISTORY, MANAGEMENT AND NOVEL TARGETED THERAPIES

Edilmar Alvarado-Tapias, Elisa Pose, Jordi Gratacós, Ana Clemente-Sánchez, Hugo Hugo López-Pelayo, Ramón Bataller

Received August 24, 2024 Accepted October 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0709 [Accepted]

View: 592 Download: 88

Correspondence

Correspondence on editorial regarding “Understanding the impact on digestive disease in the post-COVID-19 condition”

Kwanjoo Lee, Jaeyu Park, Jinseok Lee, Hayeon Lee, Yeonjung Ha, Dong Keon Yon

Received October 22, 2024 Accepted October 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0935 [Accepted]

View: 200 Download: 6

Editorial

Stroma-tology: Predicting Recurrence in Cholangiocarcinoma

Sergi Marco, Chiara Braconi

Received October 21, 2024 Accepted October 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0932 [Accepted]

View: 213 Download: 14

Momentum Towards Simplifying and Expanding Treatment for Chronic Hepatitis B: The Body of Evidence Continues to Grow

Robert J. Wong

Received October 22, 2024 Accepted October 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0929 [Accepted]

View: 148 Download: 8

Letter to the Editor

Prevalence of steatotic liver disease and associated fibrosis in the general population: an epidemiological survey

Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li

Received October 17, 2024 Accepted October 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0921 [Accepted]

View: 245 Download: 25

Urgent Need for Education on Hepatocellular Carcinoma Surveillance Among High-Risk Population in China

Lei Cai, Chao Li, Li-Yang Sun, Yong-Kang Diao, Ming-Da Wang, Tian Yang

Received September 20, 2024 Accepted October 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0813 [Accepted]

View: 300 Download: 21

Review

Long-term Outcomes and Risk Modifiers of MASLD Between Lean and Non-Lean Populations

Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim

Received August 5, 2024 Accepted October 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0631 [Accepted]

View: 886 Download: 156

Correspondence

Correspondence on letter to the editor regarding “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma”

Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim

Received October 16, 2024 Accepted October 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0916 [Accepted]

View: 259 Download: 19

Correspondence on Editorial regarding “Genetically modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Shunda Du, Karin Wisskirchen, Ke Zhang, Ulrike Protzer

Received September 23, 2024 Accepted October 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0781 [Accepted]

View: 355 Download: 15

Review

Bioactive metabolites: a clue to the link between MASLD and CKD?

Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun

Received September 9, 2024 Accepted October 18, 2024

DOI: https://doi.org/10.3350/cmh.2024.0782 [Accepted]

View: 543 Download: 75

Snapshot

MODULATION OF LYMPHATIC VESSELS IN MANAGEMENT OF LIVER DISEASE AND COMPLICATIONS

Aarti Sharma, Pinky Juneja, Shiv K Sarin, Savneet Kaur

Received September 12, 2024 Accepted October 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0793 [Accepted]

View: 254 Download: 31

Original Article

Antiviral Therapy for Chronic Hepatitis B with Mildly Elevated Aminotransferase: A Rollover Study from the TORCH-B Trial

Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, Chieh-Chang Chen, Teng-Yu Lee, Ming-Jong Bair, Jyh-Jou Chen, Yen-Tsung Huang, I-Wei Chang, Chi-Yang Chang, Chun-Ying Wu, Ming-Shiang Wu, Lein-Ray Mo, Jaw-Town Lin

Received August 8, 2024 Accepted October 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0640 [Accepted]

View: 412 Download: 57

Letter to the Editor

Chronic hepatitis B, Extrahepatic Malignancies and the Use of Antiviral Drugs

Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau

Received October 14, 2024 Accepted October 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0906 [Accepted]

View: 227 Download: 16

Original Article

Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma

Yang Liu, Fan Peng, Siyuan Wang, Huanmin Jiao, Kaixiang Zhou, Wenjie Guo, Shanshan Guo, Miao Dang, Huanqin Zhang, Weizheng Zhou, Xu Guo, Jinliang Xing

Received July 6, 2024 Accepted October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0527 [Accepted]

View: 521 Download: 83

Correspondence

Correspondence on Editorial regarding “Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease”

Young Eun Chon, Jung Hwan Yu, Seung Up Kim

Received October 6, 2024 Accepted October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0878 [Accepted]

View: 268 Download: 11

Reply to: “Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers”

Satya Priya Sharma, Ki Tae Suk

Received October 4, 2024 Accepted October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0872 [Accepted]

View: 506 Download: 31

Original Article

Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments

Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, Silvia Inés García, Adrian Salatino, Silvia Sookoian

Received May 15, 2024 Accepted October 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0359 [Accepted]

View: 575 Download: 83

Letter to the Editor

Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”

Wei Feng, Qile Wang, Qingwang Ye

Received October 8, 2024 Accepted October 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0887 [Accepted]

View: 389 Download: 15

Reply to Correspondence

Reply: Correspondence: “Transcriptomic signature in hepatocellular carcinoma to predict immunotherapy response.”

Hiroaki Kanzaki, Yujin Hoshida

Received October 8, 2024 Accepted October 9, 2024

DOI: https://doi.org/10.3350/cmh.2024.0886 [Accepted]

View: 313 Download: 11

Editorial

Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease

Won Sohn

Received September 21, 2024 Accepted October 9, 2024

DOI: https://doi.org/10.3350/cmh.2024.0823 [Accepted]

View: 287 Download: 15

Letter to the Editor

Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma

Xiping Shen, Ji Wu

Received September 13, 2024 Accepted October 9, 2024

DOI: https://doi.org/10.3350/cmh.2024.0794 [Accepted]

View: 402 Download: 25

Reply to Correspondence

Reply to: Correspondence on Editorial regarding “Genetically modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Antonio Bertoletti, Anthony T Tan

Received October 2, 2024 Accepted October 9, 2024

DOI: https://doi.org/10.3350/cmh.2024.0867 [Accepted]

View: 374 Download: 13

Letter to the Editor

Contemporary Awareness of Viral Hepatitis between 2012 and 2022 among Korean Adults

Donghee Kim, Won Kim, Aijaz Ahmed

Received September 28, 2024 Accepted October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0849 [Accepted]

View: 284 Download: 16

Editorial

Transient elastography for assessing liver fibrosis in autoimmune liver diseases: Excellent performance but limited details

Kyung-Ah Kim

Received September 22, 2024 Accepted October 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0827 [Accepted]

View: 254 Download: 13

Letter to the Editor

Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li

Received September 23, 2024 Accepted October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0832 [Accepted]

View: 299 Download: 26

Editorial

Understanding the impact on digestive disease in the post-COVID-19 condition

Yang-Hyun Baek

Received September 30, 2024 Accepted October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0856 [Accepted]

View: 248 Download: 12

Correspondence

Correspondence on Letter regarding “Personalized Approaches to the Treatment of Hepatocellular Carcinoma Using Immune Checkpoint Inhibitors”

Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee

Received September 23, 2024 Accepted October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0830 [Accepted]

View: 232 Download: 7

Correspondence on Letter regarding “Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response.”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee

Received September 23, 2024 Accepted October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0829 [Accepted]

View: 275 Download: 15

Editorial

The Urgent Need for Multidisciplinary Approaches in Managing Alcohol-Associated Liver Disease

Soon Sun Kim, Jae Youn Cheong

Received September 27, 2024 Accepted October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0847 [Accepted]

View: 238 Download: 22

Correspondence

Correspondence on the Editorial regarding “The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients”

Young-Joo Jin, Seung Up Kim

Received September 27, 2024 Accepted October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0846 [Accepted]

View: 235 Download: 10

Original Article

Self-testing strategy to eliminate Hepatitis C as per WHO’s goal: Analysis of disease burden and cost-effectiveness

Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn

Received June 26, 2024 Accepted October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0484 [Accepted]

View: 471 Download: 60

USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination

Sha Hu, Zhouxiang Wang, Kun Zhu, Hongjie Shi, Fang Qin, Tuo Zhang, Song tian, Yanxiao Ji, Jianqing Zhang, Juanjuan Qin, Zhigang She, Xiaojing Zhang, Peng Zhang, Hongliang Li

Received June 25, 2024 Accepted October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0478 [Accepted]

View: 1159 Download: 322

Review Article

Sinusoidal communication in chronic liver disease

Albert Gibert-Ramos, María Andrés-Rozas, Raül Pastó, Pablo Alfaro-Retamero, Sergi Guixé-Muntet, Jordi Gracia-Sancho

Received August 29, 2024 Accepted October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0734 [Accepted]

View: 548 Download: 117

Original Article

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation

Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi

Received June 14, 2024 Accepted September 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0451 [Accepted]

View: 510 Download: 99

Review

Roles of X-box binding protein 1 in liver pathogenesis

Jihoon Tak, Yun Seok Kim, Sang Geon Kim

Received June 10, 2024 Accepted September 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0441 [Accepted]

View: 664 Download: 74

Correspondence

Correspondence on Letter regarding “Comprehensive Analysis of Transcriptomic Biomarkers for Predicting Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma.”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee

Received September 23, 2024 Accepted September 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0828 [Accepted]

View: 347 Download: 21

Letter to the Editor

Accountability in AI Medicine: A Critical Appraisal of ChatGPT in Patient Self-Management and Screening

Jiawen Wang, Tian Xia

Received September 9, 2024 Accepted September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0769 [Accepted]

View: 282 Download: 22

Original Article

Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial

Woo Hyun Paik, Joo Kyung Park, Moon Jae Chung, Gunn Huh, Ce Hwan Park, Sang Hyub Lee, Heon Se Jeong, Hee Jin Kim, Do Hyun Park

Received August 4, 2024 Accepted September 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0629 [Accepted]

View: 574 Download: 111

Correspondence

Correspondence on Editorial regarding “Towards unification of liver stiffness measurement cutoffs”

Jung Hwan Yu, Seung Up Kim

Received September 18, 2024 Accepted September 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0815 [Accepted]

View: 317 Download: 16

Editorial

The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients

Mirko Zoncapè, Emmanuel A. Tsochatzis

Received September 18, 2024 Accepted September 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0817 [Accepted]

View: 341 Download: 23

Correspondence

Reply to Letter regarding “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”

Yuri Cho, Dae Won Jun

Received September 19, 2024 Accepted September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0818 [Accepted]

View: 294 Download: 14

Letter to the Editor

Comprehensive Analysis of Transcriptomic Biomarkers for Predicting Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma

Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu

Received August 3, 2024 Accepted September 18, 2024

DOI: https://doi.org/10.3350/cmh.2024.0628 [Accepted]

View: 426 Download: 55 Crossref: 1

Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes

Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen

Received August 27, 2024 Accepted September 13, 2024

DOI: https://doi.org/10.3350/cmh.2024.0719 [Accepted]

View: 367 Download: 34

Editorial

Towards unification of liver stiffness measurement cutoffs

Yangyue Zhang, Vincent Wai-Sun Wong

Received September 7, 2024 Accepted September 13, 2024

DOI: https://doi.org/10.3350/cmh.2024.0766 [Accepted]

View: 279 Download: 12

HCC surveillance after sustained virological response in chronic hepatitis C

Ho Soo Chun, Minjong Lee

Received September 13, 2024 Accepted September 13, 2024

DOI: https://doi.org/10.3350/cmh.2024.0795 [Accepted]

View: 289 Download: 15

Letter to the Editor

Letter regarding “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”

Xiao-Song Li, Xi-Ping Shen, Hang Li

Received September 9, 2024 Accepted September 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0784 [Accepted]

View: 350 Download: 17

Correspondence

Correspondence on Editorial regarding “Spotting Undiagnosed Significant Liver Fibrosis in the General Population: Impact on Subsequent Clinical Care”

Hee Yeon Kim, Miyoung Choi, Dae Won Jun

Received September 9, 2024 Accepted September 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0777 [Accepted]

View: 288 Download: 13

Correspondence on Letter regarding “A complement to epigenetics in MASLD”

Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim

Received September 6, 2024 Accepted September 9, 2024

DOI: https://doi.org/10.3350/cmh.2024.0761 [Accepted]

View: 324 Download: 27

Correspondence on Editorial regarding “KCTD17 as a RAS stabilizer in hepatocellular carcinoma progression”

Sang Bae Lee, KyeongJin Kim

Received September 4, 2024 Accepted September 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0750 [Accepted]

View: 349 Download: 41

PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD

Baokai Sun, Likun Zhuang

Received September 3, 2024 Accepted September 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0744 [Accepted]

View: 366 Download: 55

Editorial

Personalized Approaches to the Treatment of Hepatocellular Carcinoma Using Immune Checkpoint Inhibitors

Naoshi Nishida

Received September 1, 2024 Accepted September 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0739 [Accepted]

View: 291 Download: 24 Crossref: 1

Spotting Undiagnosed Significant Liver Fibrosis in the General Population: Impact on Subsequent Clinical Care

Nana Peng, Mary Yue Wang, Sherlot Juan Song, Terry Cheuk-Fung Yip

Received August 30, 2024 Accepted September 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0737 [Accepted]

View: 260 Download: 17

Letter to the Editor

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma

Meng-Che Wu, Hui-Chin Chang, Yi-Sheng Jhang, Shuo-Yan Gau

Received August 18, 2024 Accepted August 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0682 [Accepted]

View: 463 Download: 52

Editorial

Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response

Hiroaki Kanzaki, Yujin Hoshida

Received August 28, 2024 Accepted August 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0726 [Accepted]

View: 366 Download: 34

Correspondence

Reply to: “From invasive to intuitive: the emerging role of non-invasive models in hepatic decompensation”

Chuan Liu, Ling Yang, Hong You, Gao-Jun Teng, Xiaolong Qi

Received August 27, 2024 Accepted August 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0723 [Accepted]

View: 354 Download: 22

Editorial

Identification of KCTD17 as a RAS stabilizer in hepatocellular carcinoma

Rainbow Wing Hei LEUNG, Terence Kin Wah LEE

Received August 27, 2024 Accepted August 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0718 [Accepted]

View: 367 Download: 25

Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers

Soon Kyu Lee, Jong Young Choi

Received August 26, 2024 Accepted August 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0716 [Accepted]

View: 378 Download: 40

A complement to epigenetics in MASLD

Johanna K. DiStefano, Glenn S. Gerhard

Received August 23, 2024 Accepted August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0704 [Accepted]

View: 341 Download: 13

TM6SF2 and PNPLA3: a potential dynamic duo?

Andrea Caddeo, Rosellina M. Mancina

Received August 22, 2024 Accepted August 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0703 [Accepted]

View: 447 Download: 65

From Invasive to Intuitive: The Emerging Role of Non-Invasive Models in Hepatic Decompensation

Akhil Deshmukh, Rakhi Maiwall

Received August 13, 2024 Accepted August 13, 2024

DOI: https://doi.org/10.3350/cmh.2024.0661 [Accepted]

View: 284 Download: 15

Correspondence

Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?

Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu

Received August 6, 2024 Accepted August 13, 2024

DOI: https://doi.org/10.3350/cmh.2024.0638 [Accepted]

View: 342 Download: 20

Review Article

Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease

Zobair M. Younossi, Markos Kalligeros, Linda Henry

Received June 6, 2024 Accepted August 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0431 [Accepted]

View: 2551 Download: 630 Crossref: 5

Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation

Meng Sha, Jun Wang, Jie Cao, Zhi-Hui Zou, Xiao-ye Qu, Zhi-feng Xi, Chuan Shen, Ying Tong, Jian-jun Zhang, Seogsong Jeong, Qiang Xia

Received April 30, 2024 Accepted August 12, 2024

DOI: https://doi.org/10.3350/cmh.2024.0323 [Accepted]

View: 705 Download: 89

Letter to the Editor

Presence of liver fibrosis in chronic hepatitis B patients with varying serum HBV DNA levels

Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang

Received July 26, 2024 Accepted August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0602 [Accepted]

View: 298 Download: 21

Editorial

MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors

Rex Wan-Hin Hui, Lung-Yi Mak

Received August 4, 2024 Accepted August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0630 [Accepted]

View: 288 Download: 8

From Past to Pandemic: Health Disparities in U.S. Hepatobiliary Cancer Mortality Before and During COVID-19

Ilona Argirion

Received July 26, 2024 Accepted August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0597 [Accepted]

View: 312 Download: 19

Review

Precision medicine and nucleotide-based therapeutics to treat MASH

Andrea Caddeo, Stefano Romeo

Received June 8, 2024 Accepted August 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0438 [Accepted]

View: 1259 Download: 247 Crossref: 2

Correspondence

Correspondence to letter to the editor on "Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B"

Gi-Ae Kim, Seung Won Choi, Young-Suk Lim

Received August 1, 2024 Accepted August 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0619 [Accepted]

View: 326 Download: 22

Reply to Correspondence

Reply to correspondence regarding “UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma

Martina Mang Leng LEI, Terence Kin Wah LEE

Received August 1, 2024 Accepted August 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0621 [Accepted]

View: 332 Download: 19

Snapshot

MASLD across women’ reproductive lifespan and issues

Clara Meda, Arianna Dolce, Sara Della Torre

Received June 3, 2024 Accepted August 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0419 [Accepted]

View: 400 Download: 44

Correspondence

Correspondence on Editorial regarding “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”

Renyu Zhang, Ding Wei, Zhinan Chen, Huijie Bian

Received July 23, 2024 Accepted July 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0590 [Accepted]

View: 405 Download: 38

Editorial

UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma

Martina Mang Leng LEI, Terence Kin Wah LEE

Received July 15, 2024 Accepted July 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0568 [Accepted]

View: 727 Download: 57

Original Article

Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)

Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Liu Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi

Received March 22, 2024 Accepted July 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0198 [Accepted]

View: 1407 Download: 177 Crossref: 1

Review

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

Received April 10, 2024 Accepted June 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0246 [Accepted]

View: 2626 Download: 144 Crossref: 1

Viewed By 5042	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 4912	MAFLD: How is it different from NAFLD?
Viewed By 4421	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4345	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4291	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 197	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 137	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Ahead-of-print